Abstract
Purpose
Second-line chemotherapy has been shown to benefit patients with advanced gastric cancer (AGC), extending the overall survival (OS) and progression-free survival (PFS). This study aimed to assess the efficacy and cost-effectiveness of second-line treatment for elderly patients with AGC.
Methods
Medical records and follow-up information of elderly patients (≥70 years) with AGC who received second-line chemotherapy were collected. A Markov model comprising three health states PFS, progressive disease and death was developed to simulate the process of AGC. Cost was calculated from the perspective of Chinese society. Sensitivity analyses were applied to explore the impact of essential variables.
Results
Forty-three elderly patients with AGC receiving second-line chemotherapy were included in our study. The median OS was 6.0 months (95% confidence interval (CI) 3.90–8.10) and PFS was 3.1 months (95% CI 1.38–4.82). No treatment-related death occurred. The most frequently drug-related grade 3/4 AEs were diarrhea (2.3%), leukopenia (16.3%) and nausea (7.0%). The incremental cost-effective ratio was $18,223.75/QALY for second-line chemotherapy versus BSC, which was below the threshold of 3× the per capita GDP of China, $23,970.00.
Conclusion
Second-line chemotherapy was an optimal strategy for elderly AGC patients in China from the efficacy and cost-effectiveness perspective.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):E359–86.
Ai-wen Wu, Ji Jia-fu, Yang Hong, Li Yan-ning, Li Shuang-xi, Zhang Lian-hai, et al. Long-term outcome of a large series of gastric cancer patients in China. Chin J Cancer Res. 2010;22(22):167–75.
Zhao G, Ford ES, Ahluwalia IB, Li C, Mokdad AH. Prevalence and trends of receipt of cancer screenings among US women with diagnosed diabetes. J Gen Intern Med. 2008;24(2):270–5.
Liu Jian, Sun Li-Ping, Gong Yue-Hua, Yuan Yuan. Risk factors of precancerous gastric lesions in a population at high risk of gastric cancer. Chin J Cancer Res. 2010;22(4):267–73.
Katherine D, Neugut Al. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.
Kitamura K, Yamaguchi T, Taniguchi H, Hagiwara A, Yamane T, Sawai K, et al. Clinicopathological characteristics of gastric cancer in the elderly. Br J Cancer. 1996;73(6):798–802.
Oohara T, Johjima Y, Yamamoto O, Tohma H, Kondo Y. Gastric cancer in patients above 70 years of age. World J Surg. 1984;8(3):315–20.
Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–8.
Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(47):2306–14.
Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet. 2014;15(1):78–86.
Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 Study. J Clin Oncol. 2013;31(31):3935–43.
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak. 1993;13(4):322–38.
Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu-Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther. 2008;30:382–92.
Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011;105(9):1273–8.
https://en.wikipedia.org/wiki/List of countries by GDP (nominal) per capita. Accessed 10 May 2016.
Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438–44.
Ohba A, Takashima A, Nishiuchi T, Honma Y, Iwasa S, Okita N, et al. Second-line chemotherapy with paclitaxel for elderly patients with advanced gastric cancer. J Clin Oncol. 2016;34:108 (meeting abstracts).
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
Catalano V, Bisonni R, Graziano F, Giordani P, Alessandroni P, Baldelli AM, et al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer. 2013;16(3):411–9.
Chen XZ, Jiang K, Hu JK, Zhang B, Gou HF, Yang K, et al. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol. 2008;14(17):2715–22.
Glimelius B, Hoffman K, Graf W, Haglund U, Nyrén O, Påhlman L, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol Off J Eur Soc Med Oncol. 1995;6(3):267–74.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Ethical standards
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Research Ethics Committees of West China Hospital, Sichuan University) and with the Helsinki Declaration of 1964 and later versions.
Informed consent
All persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study were omitted.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
K. Zhou and F. Wen contributed equally to this work.
Rights and permissions
About this article
Cite this article
Zhou, K., Wen, F., Zhang, P. et al. Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer. Clin Transl Oncol 19, 1117–1124 (2017). https://doi.org/10.1007/s12094-017-1647-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-017-1647-9